The Health Technology Assessment Review options paper includes a line that explains why any stakeholder push to widen how technologies are valued faces such strong institutional resistance.
'A broader assessment of value would increase the cost and reduce the benefit to us'
February 6, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News
